epilepsiaEpilepsy and paroxysmal conditionsЭпилепсия и пароксизмальные состояния2077-83332311-4088IRBIS LLCepilepsia-61Research ArticleSCIENTIFIC SURVEYSНАУЧНЫЕ ОБЗОРЫTERATOGENESIS OF ANTIEPILEPTIC DRUGS: REVIEW AND CLINICAL CASESТЕРАТОГЕНЕЗ ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ: ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ НАБЛЮДЕНИЯДмитренкоД. В.DmitrenkoD. V.ШнайдерН. А.ShnayderN. A.Красноярский государственный медицинский университет имени профессора В. Ф. Войно-ЯсенецкогоРоссияKrasnoyarsk State Medical University named after prof. V.F. Voyno-YasenetskogoRussian Federation201403062016626170Copyright © Dmitrenko D.V., Shnayder N.A., 20162016Дмитренко Д.В., Шнайдер Н.А.Dmitrenko D.V., Shnayder N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epilepsia.su/jour/article/view/61

Abstract: The article is devoted to problem of the teratogenic effects of antiepileptic drugs. The current approaches to refining birth defects in children whose mothers took the valproic acid drugs during pregnancy are described. The authors are presented the clinical cases for discussion. 

Статья посвящена проблеме тератогенного влияния противоэпилептических препаратов. Освещены современные подходы к уточнению причин развития врожденных пороков у детей, матери которых принимали во время беременности препараты вальпроевой кислоты. Представлены клинические наблюдения авторов для обсуждения.

эпилепсияфолиевая кислотапротивоэпилептические препаратытератогенезврожденные пороки развитияклинический случайобсуждениеepilepsyfolic acidantiepileptic drugsteratogenesiscongenital malformations (birth defects)clinical casediscussionReferencesВласов П.Н. Беременность при эпилепсии. Эпилепсия и пароксизмальные состояния. 2009; 1: 8-13.Vlasov P.N. Jepilepsija i paroksizmal’nye sostojanija. 2009; 1: 8-13.Власов П.Н., Карлов В.А., Петрухин В.А. и соавт. Медикаментозная терапия эпилепсии у беременных. Фарматека. 2005; 9: 38-43.Vlasov P.N., Karlov V.A., Petruhin V.A. i soavt. Farmateka. 2005; 9: 38-43.Дмитренко Д.В., Шнайдер Н.А., Егорова А.Т. Алгоритм ведения беременности и родов у женщин, страдающих эпилепсией. Проблемы женского здоровья. 2012; 2: 63-69.Dmitrenko D.V., Shnajder N.A., Egorova A.T. Problemy zhenskogo zdorov’ja. 2012; 2: 63-69.Кантемирова Б.И., Стародубцев А.К., Сычев Д.А. и соавт. Пути совершенствования фармакотерапии эпилепсии у детей: фокус на индивидуальные особенности биотрансформации лекарственных средств. Эпилепсия и пароксизмальные состояния. 2012; 3:14-18.Kantemirova B.I., Starodubcev A.K., Sychev D.A. i soavt. Jepilepsija i paroksizmal’nye sostojanija. 2012; 3:14-18.Карлов В.А. Эпилепсия у детей и взрослых, женщин и мужчин: руководство для врачей. М. 2010; 720 с.Karlov V.A. Epilepsy in children and adults, women and men: a guide for physicians [Jepilepsija u detej i vzroslyh, zhenshhin i muzhchin: rukovodstvo dlja vrachej]. Moscow. 2010; 720 s.Кукес В.Г., Сычев Д.А., Ших Е.В. Изучение биотрансформации лекарственных средств – путь к повышению эффективности и безопасности фармакотерапии. Врач. 2007; 1: 6-8.Kukes V.G., Sychev D.A., Shih E.V. Vrach. 2007; 1: 6-8.Михеева Ю.А., Кропачева Е.С., Игнатьев И.В. и др. Полиморфизм гена цитохрома Р450 2С9 (CYP2C9) и безопасность терапии варфарином. Кардиология. 2008; 3: 77-83.Miheeva Ju.A., Kropacheva E.S., Ignat’ev I.V. i dr. Kardiologija. 2008; 3: 77-83.Пилюгина М.С. Пути метаболизма препаратов вальпроевой кислоты и карбамазепина. Вестник Клинической больницы №51. 2010; 3 (10): 52-55.Piljugina M.S. Vestnik Klinicheskoj bol’nicy №51. 2010; 3 (10): 52-55.Сироткина О.В., Улитина А.С., Тараскина А.Е. и др. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином. Российский кардиологический журн. 2004; 6: 47-50.Sirotkina O.V., Ulitina A.S., Taraskina A.E. i dr. Rossijskij kardiologicheskij zhurn. 2004; 6: 47-50.Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика. М. 2007; 230с.Sychev D.A., Ramenskaja G.V., Ignat’ev I.V., Kukes V.G. Clinical pharmacogenetics [Klinicheskaja farmakogenetika]. Moscow. 2007; 230 s.Шнайдер Н.А., Дмитренко Д.В., Пилюгина М.С. Фармакогенетика антиэпилептических препаратов. Бюллетень сибирской медицины. 2008; 4: 111-118.Shnajder N.A., Dmitrenko D.V., Piljugina M.S. Bjulleten’ sibirskoj mediciny. 2008; 4: 111-118.Шнайдер Н.А., Пилюгина М.С., Дмитренко Д.В. и соавт. Индивидуальный подход к выбору антиэпилептической терапии и клинический фармакомониторинг антиконвульсантов – путь к рациональному использованию лекарственных средств. Клиническая фармакология и терапия. 2010; 6: 178-180.Shnajder N.A., Piljugina M.S., Dmitrenko D.V. i soavt. Klinicheskaja farmakologija i terapija. 2010; 6: 178-180.Шнайдер Н.А., Пилюгина М.С., Дмитренко Д.В. и соавт. Случай аггравации эпилептических припадков на фоне применения вальпроевой кислоты у семилетнего ребенка – гомозиготного носителя минорного аллеля CYP2C9*2 гена, кодирующего изофермент цитохрома Р450 2С9. Лекарственные средства. 2011; 1 (1): 56-59.Shnajder N.A., Piljugina M.S., Dmitrenko D.V. i soavt. Lekarstvennye sredstva. 2011; 1 (1): 56-59.Шнайдер Н.А., Пилюгина М.С., Дмитренко Д.В. и соавт. Частота встречаемости нежелательных лекарственных реакций на фоне приема антиконвульсантов у больных эпилепсией. Клиническая фармакология и терапия. 2010; 6: 180-184.Shnajder N.A., Piljugina M.S., Dmitrenko D.V. i soavt. Klinicheskaja farmakologija i terapija. 2010; 6: 180-184.Шнайдер Н.А., Пилюгина М.С., Дмитренко Д.В. Стратификация больных эпилепсией по группам риска развития нежелательных лекарственных явлений на фоне приема препаратов вальпроевой кислоты. Заместитель главного врача: лечебная работа и медицинская экспертиза. 2011; 7: 50-61.Shnajder N.A., Piljugina M.S., Dmitrenko D.V. Zamestitel’ glavnogo vracha: lechebnaja rabota i medicinskaja jekspertiza. 2011; 7: 50-61.Шнайдер Н.А., Сычев Д.А., Пилюгина М.С. и соавт. Значение фармакогенетики вальпроевой кислоты в индивидуальном подходе к лечению страдающих эпилепсией женщин фертильного возраста. Журн. неврол. и психиатрии им. С.С. Корсакова. Вып. 2. Эпилепсия. 2011; 5: 31-7.Shnajder N.A., Sychev D.A., Piljugina M.S. i soavt. Zhurn. nevrol. i psihiatrii im. S.S. Korsakova. Vyp. 2. Jepilepsija. 2011; 5: 31-7.Aspinall M.G., Hamermesh R.G. Realizing the promise of personalized medicine. Harv. Bus Rev. 2007; 85 (10): 108-117.Aspinall M.G., Hamermesh R.G. Realizing the promise of personalized medicine. Harv. Bus Rev. 2007; 85 (10): 108-117.Belcastro V., Striano P., Gorgone G. et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010; 51 (2): 274-279.Belcastro V., Striano P., Gorgone G. et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010; 51 (2): 274-279.Coppola G., Ingrosso D., Operto F.F., et al. Role of folic acid depletion on homocysteine serum level in children and adolescents with epilepsy and different MTHFR C677T genotypes. Seizure. 2012; 21 (5): 340-343.Coppola G., Ingrosso D., Operto F.F., et al. Role of folic acid depletion on homocysteine serum level in children and adolescents with epilepsy and different MTHFR C677T genotypes. Seizure. 2012; 21 (5): 340-343.Finnell R. H., Buechler B.A., Kerr B.M. et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology. 1992; 42 (5): 25-31.Finnell R. H., Buechler B.A., Kerr B.M. et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology. 1992; 42 (5): 25-31.Giovannucci E., Chen J., Smith-Warner S.A. et all. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2003; 12 (10): 970-979.Giovannucci E., Chen J., Smith-Warner S.A. et all. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2003; 12 (10): 970-979.Gueant-Rodriguez R.M., Rendeli C., Namour B. et.al. Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans. Neurosci. Lett. 2003; 334 (3): 189-192.Gueant-Rodriguez R.M., Rendeli C., Namour B. et.al. Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans. Neurosci. Lett. 2003; 334 (3): 189-192.Huemer M., Ausserer B., Graninger G. et al. Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia. 2005; 46: 1677-1683.Huemer M., Ausserer B., Graninger G. et al. Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia. 2005; 46: 1677-1683.Kiang T.K., Ho P.C., Anari M.R. et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci. 2006; 94 (2): 261-271.Kiang T.K., Ho P.C., Anari M.R. et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci. 2006; 94 (2): 261-271.Kiang T.K., Ho P.C., Anari M.R. et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/CYP2C9*1 genotype. Toxicol. Sci. 2006; 94 (2): 261-271.Kiang T.K., Ho P.C., Anari M.R. et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/CYP2C9*1 genotype. Toxicol. Sci. 2006; 94 (2): 261-271.Kidd R.S., Curry T.B., Gallagher S. et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001; 11: 803-808.Kidd R.S., Curry T.B., Gallagher S. et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phen-y-toin. Pharmacogenetics. 2001; 11: 803-808.Kirke P.N., Mills J.L., Molloy A.M. et.al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ. 2004; 328 (7455): 1535-1536.Kirke P.N., Mills J.L., Molloy A.M. et.al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ. 2004; 328 (7455): 1535-1536.Kluijtmans L.A., van den Heuvel L.P., Boers G.H. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 1996; 58 (1): 35-41.Kluijtmans L.A., van den Heuvel L.P., Boers G.H. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 1996; 58 (1): 35-41.Kumari R., Lakhan R., Garg R.K. et al. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J. Human. Gen. 2011; 17 (4): 32-40.Kumari R., Lakhan R., Garg R.K. et al. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian popula-tion. Indian J. Human. Gen. 2011; 17 (4): 32-40.Lee C.R. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find. Exp. Clin. Pharmacol. 2004; 26 (6): 463-472.Lee C.R. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find. Exp. Clin. Pharmacol. 2004; 26 (6): 463-472.Linnebank M., Moskau S., Semmler A. et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Annals of Neurology. 2011; 69 (2): 352-359.Linnebank M., Moskau S., Semmler A. et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Annals of Neurology. 2011; 69 (2): 352-359.Lipton S. A., Kim W.-K., Choi Y.-B. et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc. Natl. Acad. Sci. USA. 1997; 94: 5923-5928.Lipton S. A., Kim W.-K., Choi Y.-B. et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc. Natl. Acad. Sci. USA. 1997; 94: 5923-5928.Marangos P.J., Loftus T., Wiesner J. et al. Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia. 1990; 31 (3): 239-346.Marangos P.J., Loftus T., Wiesner J. et al. Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia. 1990; 31 (3): 239-346.Mares P., Folbergrova J., Langmeier M. et al. Convulsant action of D, L-homocysteic acid and its stereoisomers in immature rats. Epilepsia. 1997; 38: 767-776.Mares P., Folbergrova J., Langmeier M. et al. Convulsant action of D, L-homocysteic acid and its stereoisomers in immature rats. Epilepsia. 1997; 38: 767-776.McIlwain, H., & Poll, J. Interaction between adenosine generated endogenously in neocortical tissue, and homocysteine and its thiolactone. Neurochemistry International. 1985; 7: 103-110.McIlwain, H., & Poll, J. Interaction between adenosine generated endogenously in neocortical tissue, and homocysteine and its thiolactone. Neurochemistry International. 1985; 7: 103-110.Mudd S.H., Skovby F., Levy H.L. et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 1985; 37: 1-31.Mudd S.H., Skovby F., Levy H.L. et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 1985; 37: 1-31.Nygaard Jensen O., Vendelin Olesen O. Folic acid and anticonvulsive drugs. Arch Neurol. 1969; 21 (2): 208-214.Nygaard Jensen O., Vendelin Olesen O. Folic acid and anticonvulsive drugs. Arch Neurol. 1969; 21 (2): 208-214.Ornoy A., Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch. Dis. Child. 1996; 75: 517-520.Ornoy A., Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch. Dis. Child. 1996; 75: 517-520.Pennell P.B. Pregnancy in women who have epilepsy. Neurol. Clin. 2004; 22: 799-20.Pennell P.B. Pregnancy in women who have epilepsy. Neurol. Clin. 2004; 22: 799-20.Pilotto A., Seripa D., Franceshi M. et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P4502C9 polymorphism. Gastroenterology. 2007; 133 (2): 465-471.Pilotto A., Seripa D., Franceshi M. et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P4502C9 polymorphism. Gastroenterology. 2007; 133 (2): 465-471.Schwarz, S., Zhou, G., Katki, A., & Rodbard, D. L-Homocysteate stimulates (3H)MK-801 biding to the phencyclidine recognition site and is thus an agonist for the N-methyl-D-aspartate-operated cation channel. Neuroscience. 1990; 37: 193-200.Schwarz, S., Zhou, G., Katki, A., & Rodbard, D. L-Homocysteate stimulates (3H)MK-801 biding to the phencyclidine recognition site and is thus an agonist for the N-methyl-D-aspartate-operated cation channel. Neuroscience. 1990; 37: 193-200.Shi Q., Savage J.E. Hufeisen SJ. et al. L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J. Pharmacol. Exp. Ther. 2003; 305 (1): 131-42.Shi Q., Savage J.E. Hufeisen SJ. et al. L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J. Pharmacol. Exp. Ther. 2003; 305 (1): 131-42.Siniscalchi A., De Sarro G., Loizzo S., Gallelli L. High plasma homocysteine and low serum folate levels induced by antiepileptic drugs in Down syndrome. JoDD. 2012; 18 (2): 70-76.Siniscalchi A., De Sarro G., Loizzo S., Gallelli L. High plasma homocysteine and low serum folate levels induced by antiepileptic drugs in Down syndrome. JoDD. 2012; 18 (2): 70-76.Tan L., Yu J.T., Sun Y.P. et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg. 2010; 112 (4): 320-323.Tan L., Yu J.T., Sun Y.P. et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg. 2010; 112 (4): 320-323.Toffoli G., Russo A., Innocenti F. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer. 2003; 103 (3): 194-199.Toffoli G., Russo A., Innocenti F. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer. 2003; 103 (3): 194-199.Tomson T., Battino D. Teratogenicity of antiepileptic drugs: State of the art. Curr. Opin. Neurol. 2005; 18: 13135-140.Tomson T., Battino D. Teratogenicity of antiepileptic drugs: State of the art. Curr. Opin. Neurol. 2005; 18: 13135-140.Tomson T., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10: 609-617.Tomson T., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10: 609-617.Tomson T., Hiilesmaa V. Epilepsy in pregnancy. BMJ. 2007; 335: 769-73.Tomson T., Hiilesmaa V. Epilepsy in pregnancy. BMJ. 2007; 335: 769-73.Vurucu S., Demirkaya E., Kul M. et al. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32 (3): 844-848.Vurucu S., Demirkaya E., Kul M. et al. Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32 (3): 844-848.Информационный ресурс: Online Mendelian Inheritance in Man (OMIM) *607093 http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607093.Information resource: Online Mendelian Inheritance in Man (OMIM) *607093 http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=607093.Информационный ресурс: http://www.personalizedmedicinecoalition.org.Information resource: http://www.personalizedmedicinecoalition.org.

The authors declare that there are no conflicts of interest present.